Document Detail

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
MedLine Citation:
PMID:  22315486     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Mantle cell lymphoma accounts for 6% of all B-cell lymphomas and is generally incurable. It is characterized by the translocation t(11;14) leading to cyclin D1 over-expression. Cyclin D1 is downstream of the mammalian target of rapamycin threonine kinase and can be effectively blocked by mammalian target of rapamycin inhibitors. We set out to examine the single agent activity of the orally available mammalian target of rapamycin inhibitor everolimus in a prospective, multicenter trial in patients with relapsed or refractory mantle cell lymphoma (NCT00516412).
DESIGN AND METHODS: Eligible patients who had received a maximum of three prior lines of chemotherapy were given everolimus 10 mg for 28 days (one cycle) for a total of six cycles or until disease progression. The primary endpoint was the best objective response. Adverse reactions, progression-free survival and molecular response were secondary endpoints.
RESULTS: Thirty-six patients (35 evaluable) were enrolled and treatment was generally well tolerated with Common Terminology Criteria grade ≥ 3 adverse events (>5%) including anemia (11%), thrombocytopenia (11%) and neutropenia (8%). The overall response rate was 20% (95% CI: 8-37%) with two complete remissions and five partial responses; 49% of the patients had stable disease. At a median follow-up of 6 months, the median progression-free survival was 5.5 months (95% CI: 2.8-8.2) overall and 17.0 (6.4-23.3) months for 18 patients who received six or more cycles of treatment. Three patients achieved a lasting complete molecular response, as assessed by polymerase chain reaction analysis of peripheral blood.
CONCLUSIONS: Everolimus as a single agent is well tolerated and has anti-lymphoma activity in relapsed or refractory mantle cell lymphoma. Further studies of everolimus in combination with chemotherapy or as a single agent for maintenance treatment are warranted.
Christoph Renner; Pier Luigi Zinzani; Rémy Gressin; Dirk Klingbiel; Pierre-Yves Dietrich; Felicitas Hitz; Mario Bargetzi; Walter Mingrone; Giovanni Martinelli; Andreas Trojan; Krimo Bouabdallah; Andreas Lohri; Emmanuel Gyan; Christine Biaggi; Sergio Cogliatti; Francesco Bertoni; Michele Ghielmini; Peter Brauchli; Nicolas Ketterer;
Related Documents :
19356236 - Treatment of early uterine sarcomas: disentangling adjuvant modalities.
22367706 - Neoadjuvant chemotherapy in mri-staged high-risk rectal cancer in addition to or as an ...
22919026 - Smile for natural killer (nk)/t-cell lymphoma: analysis of safety and efficacy from the...
15588876 - Management of soft tissue sarcomas (sts) in first isolated local recurrence: a retrospe...
19577816 - Pemetrexed in the treatment of advanced non-squamous lung cancer.
9784326 - Treosulfan as an effective second-line therapy in ovarian cancer.
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2012-02-07
Journal Detail:
Title:  Haematologica     Volume:  97     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-07-16     Completed Date:  2012-12-31     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  1085-91     Citation Subset:  IM    
Division of Oncology, University Hospital Zürich, Rämistrasse 100 8091 Zürich, Switzerland.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Disease-Free Survival
Drug Administration Schedule
Lymphoma, Mantle-Cell / drug therapy*,  mortality
Middle Aged
Neoplasm Proteins / antagonists & inhibitors
Neoplasm Staging
Prospective Studies
Protein Kinase Inhibitors / administration & dosage*,  adverse effects
Remission Induction
Sirolimus / administration & dosage,  adverse effects,  analogs & derivatives*
TOR Serine-Threonine Kinases / antagonists & inhibitors
Reg. No./Substance:
0/Neoplasm Proteins; 0/Protein Kinase Inhibitors; 159351-69-6/everolimus; 53123-88-9/Sirolimus; EC protein, human; EC Serine-Threonine Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Invasive Pneumococcal Disease in Infants Younger Than 60 Days.
Next Document:  Impact of body-mass index in the outcome of adult patients with acute myeloid leukemia.